- Home
- BAK vs CVAC Comparison
BAK vs CVAC Comparison
Compare BAK & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAK | CVAC |
|---|---|---|
| Founded | 1972 | 2000 |
| Country | Brazil | Germany |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BAK | CVAC |
|---|---|---|
| Price | $2.84 | $5.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 3 |
| Target Price | $4.40 | ★ $6.83 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 11-11-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | N/A | ★ 0.94 |
| Revenue | ★ $13,841,708,237.00 | $83,000,117.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.62 | $23.40 |
| P/E Ratio | ★ N/A | $5.62 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.32 | $2.48 |
| 52 Week High | $5.26 | $5.72 |
Technical Indicators
Market Signals| Indicator | BAK | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 46.21 |
| Support Level | $2.89 | $4.95 |
| Resistance Level | $3.05 | $5.55 |
| Average True Range (ATR) | 0.18 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 24.30 | 45.83 |
Price Performance
Historical ComparisonAbout BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.